Drug Trial Radar · NCT03417102
A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients With Inhibitors
Last checked: Nov 19, 2026Latest source record: Mar 28, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
60
Actual
Start
Feb 14, 2018
Primary completion
Nov 25, 2020
Study completion Jun 23, 2021
Sponsor
- Lead sponsor
- Genzyme, a Sanofi CompanySanofi (SNY)
- Sponsor type
- Industry
- First posted
- Jan 31, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study was to determine the frequency of bleeding episodes in participants receiving fitusiran as prophylactic treatment of hemophilia compared to participants who were assigned to continue with their regular medication. In addition, the study assessed safety, quality of life, pharmacodynamics (PD), and pharmacokinetics (PK).
Conditions
- Hemophilia A
- Hemophilia B
Interventions
fitusiranDrug
solution for injection; by subcutaneous (SC) injection
Bypassing agentsDrug
solution for injection; by intravenous (IV) injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Estimated Annualized Bleeding Rate (ABR) for Treated Bleeds During the Efficacy PeriodTime frame: From Day 29 up to Day 246 or up to the last day of bleeding follow up (any day up to Day 246), whichever was the earliest
- Observed Annualized Bleeding Rate (ABR) for Treated Bleeds During the Efficacy PeriodTime frame: From Day 29 up to Day 246 or up to the last day of bleeding follow up (any day up to Day 246), whichever was the earliest
Locations
58 sites in 17 countries. Site status is shown where the registry gives one.
Investigational Site Number 0117
Phoenix, Arizona
Investigational Site Number 0139
Los Angeles, California
Investigational Site Number 0135
Orange, California
Investigational Site Number 0137
San Diego, California
Investigational Site Number 0128
Gainesville, Florida
Investigational Site Number 0115
Jacksonville, Florida
Investigational Site Number 0105
Miami, Florida
Investigational Site Number 0103
Tampa, Florida
Investigational Site Number 0119
New Orleans, Louisiana
Investigational Site Number 0136
Baltimore, Maryland
Investigational Site Number 0111
Las Vegas, Nevada
Investigational Site Number 0104
Philadelphia, Pennsylvania
Investigational Site Number 6101
Camperdown, Australia
Investigational Site Number 6104
Clayton, Australia
Investigational Site Number 1102
Montreal, Canada
Investigational Site Number 8604
Beijing, China
Investigational Site Number 8602
Guangzhou, China
Investigational Site Number 8605
Hangzhou, China
Investigational Site Number 8603
Shanghai, China
Investigational Site Number 8601
Tianjin, China
Investigational Site Number 3303
Lyon, France
Investigational Site Number 3301
Rouen, France
Investigational Site Number 4905
Frankfurt am Main, Germany
Investigational Site Number 4906
Leipzig, Germany
Investigational Site Number 9102
Bangalore, India
Investigational Site Number 9108
India, India
Investigational Site Number 9104
Jaipur, India
Investigational Site Number 9106
Lucknow, India
Investigational Site Number 9103
Pune, India
Investigational Site Number 9111
Pune, India
Investigational Site Number 9105
Vellore, India
Investigational Site Number 3901
Florence, Italy
Investigational Site Number 3904
Padua, Italy
Investigational Site Number 8110
Japan, Japan
Investigational Site Number 8103
Kita Kyushu-Shi, Japan
Investigational Site Number 6003
Kota Kinabalu, Malaysia
Investigational Site Number 6004
Malaysia, Malaysia
Investigational Site Number 2701
Parktown, South Africa
Investigational Site Number 2703
Polokwane, South Africa
Investigational Site Number 2702
Port Elizabeth, South Africa
Showing 40 of 58 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.